Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

2.6K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.6K
Lineage Commitment01:21

Lineage Commitment

4.6K
Commitment is the  process whereby stem cells:
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic loss of MLH1/PMS2 loci defines a mismatch repair deficient subgroup in monomorphic epitheliotropic intestinal T-cell lymphoma.

Blood cancer journal·2026
Same author

Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study.

Journal of hematology & oncology·2026
Same author

Characteristics and outcome of intra-abdominal desmoid-type fibromatosis.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026
Same author

Prognostic Value of Combined Baseline FDG PET/CT Radiomic Parameters in Primary Mediastinal B-Cell Lymphoma.

Blood advances·2026
Same author

Long-term outcome of allogeneic hematopoietic cell transplantation for T-cell prolymphocytic leukemia - a study on behalf of the Chronic Malignancies Working Party of the EBMT.

Haematologica·2026
Same author

Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.

Blood advances·2026

Related Experiment Video

Updated: Apr 20, 2026

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

13.4K

[Plasma cell leukemia].

Aurélie Ravinet1, Jacques Olivier Bay1, Olivier Tournilhac1

  • 1Inserm CIC-501, EA 3846, CHU de Clermont-Ferrand, Hôpital Estaing, Service de thérapie cellulaire et d'hématologie clinique adulte, 1, place Lucie-Aubrac, 63003 Clermont-Ferrand cedex 01, France.

Bulletin Du Cancer
|November 25, 2014
PubMed
Summary

Plasma cell leukemia (PCL) is a rare blood cancer. Advances in novel agents and stem cell transplantation have improved outcomes for patients with this aggressive disease.

Keywords:
allogeneic stem cell transplantationautologous stem cell transplantationbortezomibmultiple myelomaplasma cell leukemia

More Related Videos

Author Spotlight: Identification and Isolation of Quiescent Leukemia Stem Cells from Zebrafish T-ALL
06:41

Author Spotlight: Identification and Isolation of Quiescent Leukemia Stem Cells from Zebrafish T-ALL

Published on: July 19, 2024

1.5K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.9K

Related Experiment Videos

Last Updated: Apr 20, 2026

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

13.4K
Author Spotlight: Identification and Isolation of Quiescent Leukemia Stem Cells from Zebrafish T-ALL
06:41

Author Spotlight: Identification and Isolation of Quiescent Leukemia Stem Cells from Zebrafish T-ALL

Published on: July 19, 2024

1.5K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.9K

Area of Science:

  • Hematology
  • Oncology
  • Rare Diseases

Context:

  • Plasma cell leukemia (PCL) is a rare hematologic malignancy.
  • It can arise de novo (primary) or secondary to multiple myeloma.
  • PCL is characterized by specific diagnostic criteria in peripheral blood plasma cells.

Purpose:

  • To provide a comprehensive overview of plasma cell leukemia.
  • To discuss the clinical presentation, including extramedullary involvement and organ dysfunction.
  • To review current and emerging therapeutic strategies for PCL.

Summary:

  • PCL involves specific cytogenetic abnormalities and mutations facilitating immune evasion.
  • Treatment has advanced with combination therapies including novel agents like bortezomib and lenalidomide.
  • Stem cell transplantation, both autologous and allogeneic, offers therapeutic options.

Impact:

  • Improved treatment outcomes for patients with plasma cell leukemia.
  • Highlights the importance of novel agents and transplantation in managing PCL.
  • Provides a resource for understanding therapeutic recommendations for this severe disease.